Anjali D Deshpande1, Mario Schootman2, Allese Mayer2. 1. Division of General Medical Sciences, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO. Electronic address: adeshpan@dom.wustl.edu. 2. Department of Epidemiology, College for Public Health and Social Justice, Saint Louis University, St. Louis, MO.
Abstract
PURPOSE: To examine the validity of claims data to identify colorectal cancer (CRC) recurrence and determine the extent to which misclassification of recurrence status affects estimates of its association with overall survival in a population-based administrative database. METHODS: We calculated the accuracy of claims data relative to medical records from one large tertiary hospital to identify CRC recurrence. We estimated the effect of misclassifying recurrence on survival by applying these findings to the linked Surveillance, Epidemiology, and End Results-Medicare data. RESULTS: Of 174 eligible CRC patients identified through medical records, 32 (18.4%) had a recurrence. A claims-based algorithm of secondary malignancy codes yielded a sensitivity of 81% and specificity of 99% for identifying recurrence. Agreement between data sources was almost perfect (kappa: 0.86). In a model unadjusted for misclassification, CRC patients with recurrence were 3.04 times (95% confidence interval: 2.92-3.17) more likely to die of any cause than those without recurrence. In the corrected model, CRC patients with recurrence were 3.47 times (95% confidence interval: 3.06-4.14) more likely to die than those without recurrence. CONCLUSIONS: Identifying recurrence in CRC patients using claims data is feasible with moderate sensitivity and high specificity. Future studies can use this algorithm with Surveillance, Epidemiology, and End Results-Medicare data to study treatment patterns and outcomes of CRC patients with recurrence.
PURPOSE: To examine the validity of claims data to identify colorectal cancer (CRC) recurrence and determine the extent to which misclassification of recurrence status affects estimates of its association with overall survival in a population-based administrative database. METHODS: We calculated the accuracy of claims data relative to medical records from one large tertiary hospital to identify CRC recurrence. We estimated the effect of misclassifying recurrence on survival by applying these findings to the linked Surveillance, Epidemiology, and End Results-Medicare data. RESULTS: Of 174 eligible CRCpatients identified through medical records, 32 (18.4%) had a recurrence. A claims-based algorithm of secondary malignancy codes yielded a sensitivity of 81% and specificity of 99% for identifying recurrence. Agreement between data sources was almost perfect (kappa: 0.86). In a model unadjusted for misclassification, CRCpatients with recurrence were 3.04 times (95% confidence interval: 2.92-3.17) more likely to die of any cause than those without recurrence. In the corrected model, CRCpatients with recurrence were 3.47 times (95% confidence interval: 3.06-4.14) more likely to die than those without recurrence. CONCLUSIONS: Identifying recurrence in CRCpatients using claims data is feasible with moderate sensitivity and high specificity. Future studies can use this algorithm with Surveillance, Epidemiology, and End Results-Medicare data to study treatment patterns and outcomes of CRCpatients with recurrence.
Authors: Jessica Chubak; Onchee Yu; Gaia Pocobelli; Lois Lamerato; Joe Webster; Marianne N Prout; Marianne Ulcickas Yood; William E Barlow; Diana S M Buist Journal: J Natl Cancer Inst Date: 2012-04-30 Impact factor: 13.506
Authors: Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: Michael J Hassett; Debra P Ritzwoller; Nathan Taback; Nikki Carroll; Angel M Cronin; Gladys V Ting; Deb Schrag; Joan L Warren; Mark C Hornbrook; Jane C Weeks Journal: Med Care Date: 2014-10 Impact factor: 2.983
Authors: Joan L Warren; K Robin Yabroff; Angela Meekins; Marie Topor; Elizabeth B Lamont; Martin L Brown Journal: J Natl Cancer Inst Date: 2008-06-10 Impact factor: 13.506
Authors: Craig C Earle; Ann B Nattinger; Arnold L Potosky; Kathleen Lang; Rajiv Mallick; Mark Berger; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Joan L Warren; Angela Mariotto; Danielle Melbert; Deborah Schrag; Paul Doria-Rose; David Penson; K Robin Yabroff Journal: Med Care Date: 2016-08 Impact factor: 2.983
Authors: Alvaro Figueredo; R Bryan Rumble; Jean Maroun; Craig C Earle; Bernard Cummings; Robin McLeod; Lisa Zuraw; Caroline Zwaal Journal: BMC Cancer Date: 2003-10-06 Impact factor: 4.430
Authors: Deborah A Marshall; Lina Burgos-Liz; Kalyan S Pasupathy; William V Padula; Maarten J IJzerman; Peter K Wong; Mitchell K Higashi; Jordan Engbers; Samuel Wiebe; William Crown; Nathaniel D Osgood Journal: Pharmacoeconomics Date: 2016-02 Impact factor: 4.981
Authors: Alpha Oumar Diallo; Asha Krishnaswamy; Stuart K Shapira; Matthew E Oster; Mary G George; Jenna C Adams; Elizabeth R Walker; Paul Weiss; Mohammed K Ali; Wendy Book Journal: J Am Med Inform Assoc Date: 2018-12-01 Impact factor: 4.497
Authors: Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Debra Ritzwoller Journal: Med Care Date: 2017-12 Impact factor: 2.983
Authors: Hava Izci; Tim Tambuyzer; Krizia Tuand; Victoria Depoorter; Annouschka Laenen; Hans Wildiers; Ignace Vergote; Liesbet Van Eycken; Harlinde De Schutter; Freija Verdoodt; Patrick Neven Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Hajime Uno; Debra P Ritzwoller; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Michael J Hassett Journal: JCO Clin Cancer Inform Date: 2018-12